Astellas Pharma Inc 2015 IR
The report outlines Astellas' performance and strategic initiatives for fiscal 2014, focusing on turning advances in science into value for patients. The company introduced its Strategic Plan 2015-2017, targeting a return on equity of 15% or more and prioritizing R&D investments in new therapeutic areas like muscle diseases and ophthalmology. Astellas advanced its Network Research System to foster open innovation and collaborated on addressing Access to Health issues, such as neglected tropical diseases. Additionally, the company made progress on its environmental goals, reducing greenhouse gas emissions by 30.2% and water withdrawal by 22.8% compared to fiscal 2005 levels.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2015
Type: IR
Pages: 156
Astellas Pharma Inc
Annual Report
The report outlines Astellas' performance and strategic initiatives for fiscal 2014, focusing on turning advances in science into value for patients. The company introduced its Strategic Plan 2015-2017, targeting a return on equity of 15% or more and prioritizing R&D investments in new therapeutic areas like muscle diseases and ophthalmology. Astellas advanced its Network Research System to foster open innovation and collaborated on addressing Access to Health issues, such as neglected tropical diseases. Additionally, the company made progress on its environmental goals, reducing greenhouse gas emissions by 30.2% and water withdrawal by 22.8% compared to fiscal 2005 levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Apr 1, 2014 - Mar 31, 2015
Fiscal Year
2014
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Employees